Mobisante reels in $4.2M to market its ultrasound mobile app

Mobisante, a maker of ultrasound imaging systems designed for smartphones and tablets, has pulled in nearly $4.2 million of a hoped-for $5.3 million funding round, according to a U.S. regulatory filing.

The Redmond, WA, company plans to use the cash to boost sales and marketing efforts in a bid to boost the adoption of point-of-care ultrasound.

Execs previously announced the Series A equity financing but did not disclose the amount. They revealed some of their backers, however. WRF Capital led the investor syndicate, which also included the W Fund, several members of the Alliance of Angels and other angel investors. About $2.3 million of the total represents a conversion of outstanding debt financing into equity, the filing states.

Sailesh Chutani

As Xconomy reports, Mobisante first won FDA approval in February 2011 for an ultrasound device that functions on a smartphone. CEO Sailesh Chutani told Xconomy that beyond boosting sales and marketing, the funding will help the company build up cloud computing capacity for the ultrasound images its devices record.

Mobisante's target market includes orthopedics and sports medicine as well as emergency rooms, Chutani is quoted in the Xconomy piece as saying.

An initial cluster of medical-related apps hit the market without going through the FDA approval process. Mobisante was one of the first to consciously follow that path, though its future competitors will need to seek FDA approval because apps are increasingly considered to be devices.

- read the release
- here's the SEC filing
- check out Xconomy's take

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.